Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 1
2014 2
2015 2
2016 2
2017 1
2018 2
2019 1
2020 3
2021 2
2022 1
2023 4
2024 5
2025 4
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.
Hou J, Lim SG, Buti M, Yuen MF, Gane E, Lampertico P, Terrault N, Nguyen H, Yim HJ, Xie Q, Lin J, Qiu Y, Jeng WJ, Heo J, Peng CY, Chen CH, Chuang WL, Xie Y, Hlebowicz M, Idriz N, Mehta R, Agarwal K, Gomes da Silva MM, Franca A, Cernat R, Leerapun A, Coffin CS, Gadano A, Andreone P, Fujiyama S, Sevastianos V, Suzuki Y, Ratziu V, Riachi G, Stocker H, Lim TH, Asselah T, Tanaka Y, Holmes J, Liang X, Cremer J, Lukić T, Plein H, Quinn G, Tao Y, Paff M, Theodore D, Elston R; B-Well Study Group. Hou J, et al. N Engl J Med. 2026 Jun 25;394(24):2395-2406. doi: 10.1056/NEJMoa2515131. Epub 2026 May 28. N Engl J Med. 2026. PMID: 42206582 Clinical Trial.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Free PMC article. Clinical Trial.
Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, Lu J, Li X, Gao Y, Lei L, Liu J, Li J; ESPRIT Collaborative Group. Liu J, et al. Lancet. 2024 Jul 20;404(10449):245-255. doi: 10.1016/S0140-6736(24)01028-6. Epub 2024 Jun 27. Lancet. 2024. PMID: 38945140 Clinical Trial.
Mortality and Morbidity in Adults With Rheumatic Heart Disease.
Karthikeyan G, Ntsekhe M, Islam S, Rangarajan S, Avezum A, Benz A, Cabral TTJ, Changsheng M, Chillo P, Gonzalez-Hermosillo JA, Gitura B, Damasceno A, Dans AML, Davletov K, Elghamrawy A, ElSayed A, Fana GT, Gondwe L, Haileamlak A, Kayani AM, Lwabi P, Maklady F, Molefe-Baikai OJ, Musuku J, Ogah OS, Paniagua M, Rusingiza E, Sharma SK, Zuhlke L, Connolly S, Yusuf S; INVICTUS Investigators. Karthikeyan G, et al. JAMA. 2024 Jul 9;332(2):133-140. doi: 10.1001/jama.2024.8258. JAMA. 2024. PMID: 38837131 Free PMC article.
Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
Guo X, Sun G, Xu Y, Zhou S, Song Q, Li Y, Ouyang N, Li G, Cheng Z, Ye N, Wang J, Zhou Y, Yang H, Shi C, Wang C, Liu S, Zhu W, Moran AE, Ning G, Bi Y, Wang W, Cai J, Li J, Sun Y; BPRULE Study Group. Guo X, et al. Lancet. 2025 Sep 6;406(10507):1009-1019. doi: 10.1016/S0140-6736(25)01391-1. Epub 2025 Aug 31. Lancet. 2025. PMID: 40902616
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.
Cao Z, Wong F, Choudhury AK, Kamath PS, Topazian M, Torre A, Hayes PC, George J, Idilman R, Seto WK, Desalegn H, Alvares-da-Silva MR, Bush BJ, Thacker LR, Xie Q, Bajaj JS; CLEARED Consortium. Cao Z, et al. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):997-1009. doi: 10.1016/S2468-1253(24)00224-3. Epub 2024 Sep 5. Lancet Gastroenterol Hepatol. 2024. PMID: 39243795
Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.
Wong F, Adebayo D, George J, Idilman R, Hayes PC, Alvares-da-Silva MR, Torre A, Mekonnen HD, Seto WK, Sarin SK, Cao Z, Rajoriya N, Nagral A, Fisseha H, Kulkarni AV, Zhu C, Debzi N, Farias AQ, Su M, Goel A, Marciano S, Livingstone R, Dhiman RK, Gao Y, Malé-Velázquez R, Demitars CO, Bera C, Jiang YF, Velarde-Ruiz Velasco JA, Tan HK, Zhao C, Huezo MSG, Asrani SK, Wang L, Lu M, Michalczuk MT, Barutcu S, Cordova-Gallardo J, Gofton C, Gounder M, Shaw J, Albhaisi S, Zheng X, Aravinthan A, Rajaram RB, Jothimani D, Thanapirom K, Benitez C, Dincer D, Saraya A, Xu B, Lin M, Wu X, Liu C, Reddy R, Bush B, Thacker LR, Topazian M, Xie Q, Silvey S, Kamath PS, Choudhury A, Bajaj JS; CLEARED Investigators. Wong F, et al. Gut. 2026 Jun 5:gutjnl-2025-336802. doi: 10.1136/gutjnl-2025-336802. Online ahead of print. Gut. 2026. PMID: 42248676
Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.
Bajaj JS, Choudhury AK, Xie Q, Kamath PS, Topazian M, Hayes PC, Torre A, Desalegn H, Idilman R, Cao Z, Alvares-da-Silva MR, George J, Bush BJ, Thacker LR, Wong F; CLEARED Investigators. Bajaj JS, et al. Lancet Gastroenterol Hepatol. 2023 Jul;8(7):611-622. doi: 10.1016/S2468-1253(23)00098-5. Epub 2023 May 22. Lancet Gastroenterol Hepatol. 2023. PMID: 37230109 Free PMC article.
Liver Failure, Hepatic Encephalopathy, and Infection Contribute to Mortality Risk in a Global Cirrhosis Cohort.
Bajaj JS, Silvey S, Mullan A, Choudhury A, Wong F, George J, Idilman R, Topazian M, Seto WK, Torre A, Hayes P, Thacker LR, Bush BJ, Alvares da Silva M, Xie Q, Kamath PS; CLEARED Investigators. Bajaj JS, et al. Clin Gastroenterol Hepatol. 2026 Feb;24(2):453-462.e14. doi: 10.1016/j.cgh.2025.06.021. Epub 2025 Jul 5. Clin Gastroenterol Hepatol. 2026. PMID: 40618943 Free PMC article.
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
Kudo M, Abou-Alfa GK, Ren Z, Heo J, Lencioni R, Arai Y, Bouattour M, Gonzalez-Carmona MA, Guo Y, Xu AB, Alves GV, Dechaphunkul A, Ho GF, Lim YN, Hu H, Liu R, Gu S, Ostwal V, Manasirisuk W, Chiu CF, Tekumalla SH, Shroff M, Dave V, Rahma O, Erinjeri JP, Fan J; EMERALD-3 Investigators. Kudo M, et al. Lancet Oncol. 2026 Sep;27(9):1077-1093. doi: 10.1016/S1470-2045(26)00278-0. Lancet Oncol. 2026. PMID: 42636832 Clinical Trial.
33 results